Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986497 |
| Synonyms | |
| Therapy Description |
BMS-986497 is an antibody conjugate comprising a GSPT1 degrader linked to a CD33-targeting antibody, which may lead to growth inhibition of CD33-expressing tumors (Cancer Res (2023) 83 (7_Supplement): 2700). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986497 | ORM-6151|ORM6151|ORM 6151|BMS 986497|BMS986497 | BMS-986497 is an antibody conjugate comprising a GSPT1 degrader linked to a CD33-targeting antibody, which may lead to growth inhibition of CD33-expressing tumors (Cancer Res (2023) 83 (7_Supplement): 2700). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06419634 | Phase I | Azacitidine + BMS-986497 + Venetoclax BMS-986497 Azacitidine + BMS-986497 | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | FRA | ESP | CAN | 0 |